Small Cap Breaking News You Can’t Miss! Here is your daily small-cap news summary, covering the top stories from today's press releases.HPQ Silicon Inc. (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08) reported that 21700 cylindrical cells manufactured using Novacium's GEN4 silicon-based anode material achieved an average discharge capacity exceeding 6,600 mAh, with a record cell reaching 6,696 mAh. Energy density was confirmed at 319.9 Wh/kg and 906.2 Wh/L, representing a 45% improvement over graphite baseline and a 9% advance over GEN3. The company holds exclusive North American rights to commercialize Novacium's GEN3 and GEN4 materials under the HPQ ENDURA+ brand.Predictiv AI Inc. (CSE: PAI, FWB: 7IT) announced the filing of a patent application covering its method for training domain-specific clinical AI models and generating structured clinical reasoning outputs. The company introduced its Clinical AI Reasoning Platform, an extension of CloudRep.ai designed to support medical decision-making through consistent, transparent reasoning using custom small language models. Predictiv AI has begun preparations for a controlled pilot with a select group of clinics.Silver Hammer Mining Corp. (CSE: HAMR) reported positive assay results from its Phase 1 drill program on the 100% owned Silverton Silver Mine Project in Nye County, Nevada. Key intercepts included 361 g/t Ag over 1.52m and 163 g/t Ag over 1.52m, with surface rock samples assaying up to 581 g/t Ag. The mineralization extends below the reported depths of the historic Silverton mine workings, pointing to potential discovery of a chimney and manto CRD-type silver mineralization at depth.

Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) announced publication of a preclinical study in the Journal of Nanobiotechnology demonstrating that its Targeted Hyperthermia Therapy (THT) combined with PD-1 inhibitor immunotherapy resulted in 38% of animals being alive and cancer-free at 45 days in a colorectal cancer model. Notably, 100% of animals in the THT treatment group responded to immunotherapy compared to 0% in the immunotherapy-alone group. The results build on prior research in melanoma and breast cancer and lay the foundation for a future human trial combining THT with immunotherapy.SOL Strategies Inc. (CSE: HODL, NASDAQ: STKE) announced a definitive agreement to acquire the assets of Darklake Labs Pte. Ltd. for USD $1.2 million, payable primarily in common shares. Darklake developed Zyga, a zero-knowledge proof system built natively for the Solana blockchain that enables private transaction execution while eliminating front-running and sandwich attacks. The Darklake founders and core team, with experience from Meta, IBM, and Coinbase, are expected to join SOL Strategies.The AGORACOM Small Cap Daily Show is your go-to source for the best small-cap headlines, serving over 65 million investors since 2007.

Listen to today's show on your favourite podcast platform.Spotify: https://open.spotify.com/show/74mVPkfalaWXFYY65A2XLM